Please use this identifier to cite or link to this item:
Title: Biosimilars : the perception amongst Maltese clinicians
Authors: Cassar, Kathlene
Zammit Dimech, David
Grech, Louise
Balzan, Dustin
Cutajar, Anthony
Cassar, Paul John
Keywords: Biosimilar pharmaceuticals
Drugs -- Generic substitution
Biosimilar pharmaceuticals -- Research -- Malta
Pharmaceutical biotechnology -- Attitudes -- Malta
Physicians -- Attitudes -- Malta
Issue Date: 2016-06
Publisher: University of Malta. Department of Pharmacy
Citation: Cassar, K., Zammit Dimech, D., Grech, L., Balzan, D., Cutajar, A., & Cassar, P. J. (2016, June). Biosimilars: the perception amongst Maltese clinicians. Poster session presented at the EULAR (European Annual League against Rheumatism) Annual conference, London, United Kingdom.
Abstract: A poster presentation regarding the perception amongst Maltese clinicians on biosimilars. Introduction: A biosimilar product is biologic in origin. It is highly similar to another biological medicinal product (reference product), which has already been authorised by a competent regulatory authority such as the European Medicines Agency. It must have no clinically meaningful difference in terms of safety, purity and potency when compared to the reference product. The availability of biosimilar infliximab on the National Health System in Malta introduced issues related to safety, switchability and interchangeability. Aims: • To assess the perception and awareness of Maltese clinicians working within the National Health System on the concept of biosimilars.
Appears in Collections:Scholarly Works - FacM&SPha

Files in This Item:
File Description SizeFormat 
Biosimilars_the_perception_amongst_Maltese_clinicians_2016.pdf267.38 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.